Radium-223 chloride

Drug Profile

Radium-223 chloride

Alternative Names: AC1O4D1M; Alpharadin; ATI-BC-1; BAY88-8223; Radium Ra 233 dichloride; Radium-223; Radium-223 dichloride; Xofigo

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Algeta
  • Developer Algeta; Bayer HealthCare; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bone metastases
  • Phase I/II Multiple myeloma
  • Phase I Osteosarcoma
  • Discontinued Cancer pain

Most Recent Events

  • 01 Apr 2017 Parmacodynamics data from preclinical studies in Multiple myeloma presented at the 108th Annual Meeting of the American Association for Cancer Research
  • 10 Feb 2017 Phase-I/II clinical trials in Multiple myeloma (Combination therapy, Early-stage disease, Second-line therapy or greater) in South Korea (IV) (NCT02928029)
  • 31 Oct 2016 Bayer completes a phase I trial in Bone metastases (Combination therapy) in USA, Israel and Finland (IV) (NCT02442063)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top